Report      Database

    Alzheimer's Disease Patients & Market Worldwide, Future Scenario (2010 - 2015) & Drugs Analysis

    Date: 08 Jun, 2011              Type: Life Science              Pages: 95

    Alzheimer's Disease Patients & Market Worldwide, Future Scenario (2010 - 2015) & Drugs Analysis
    • Electronic Access - Single User License
      $950.00
    • CD-ROM Mail Delivery
      $1,050.00
    • Hard-copy Mail Delivery
      $1,050.00
    • Electronic Access - Multi User License
      $1,700.00

    Alzheimer’s Disease - Market Overview
     
    Alzheimer’s is a complex disease and there is no single “magic bullet” available in the market to prevent or cure it. Though many marketed drugs have been approved for Alzheimer’s disease, but it still remains a significant area of unmet medical need. Clinical success has proven elusive; however, numerous companies are developing novel treatments. Currently there’s no cure for Alzheimer’s and its still waiting for its key product. In addition, all current marketed products are going to be generic in the next five years.
     
    In 2010, there were more than 30 Million people suffering with Alzheimer’s disease but it is anticipated that by 2015 over 35 Million people worldwide will be suffering from this disease. Much of this increase will be due to increase in number of people with Alzheimer’s in low and middle income countries. Since the risk of getting the disease increases with age, the number of patients with the illness to be found in any community will depend on the proportion of older people in the group. Traditionally, the developed countries have large proportions of elderly people, and so they have many cases of Alzheimer’s disease in the community at one time. However, developing countries are also undergoing a demographic transition so that more and more persons are surviving to an old age.
     
    Global Alzheimer’s disease has increased manifold and expected to cross US$ 19 Billion by 2015. North America controls more than 50% of the total Alzheimer’s drug market share in 2010. Over the past years, the Alzheimer’s disease market has been flagged with several drugs into the market. Till last year Aricept was the world best selling drug which lost patent protection in November 2010, a milestone that will be followed by a rapid loss in sales. But there are other drugs which has the potential to become blockbuster drug by 2010. Namenda, Exelon has shown alluring growth in the market and become blockbusters in 2010. Ebixa a drug of Memantine group is expected to have a Billion dollar market by 2014. Given the alarming worldwide growth in Alzheimer’s patients, and especially if companies are able to address major unmet needs, the outlook for the Alzheimer’s disease market is excellent.  
     
    Report Details
     
    Renub Research report titled “Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 – 2015) & Drugs Analysis” studies the Alzheimer’s Disease patients prevalence worldwide and region wise. The report provides data on the Alzheimer’s Disease market Worldwide, North America, Europe and Rest of the world. 
     
    Alzheimer’s drugs such as Exelon, Aricept, Namenda, Razadyne, Axura, Ebixa, Nootropil, Prometax, Memac, Eranz market past, present and future scenario has been analyzed in this report. 
     
    Key questions answered in the report?
     
    •    Which regions have the highest prevalence of Alzheimer’s Disease diseases today and by 2050? 
    •    What is the market share accounted by Alzheimer’s disease drugs in the global markets?
    •    What is the market share accounted by the region in the global market?  
    •    Which drugs have patent expiry and future forecast of drug sales?
     
    Research Highlights
     
    •    More than 35 Million people are expected to suffer from Alzheimer’s disease by 2015 worldwide.
    •    By 2050, 59 percent of the world’s Alzheimer’s cases will live in Asia.
    •    Global Alzheimer’s disease market is expected to cross the figure of US$ 19 Billion by 2015.
    •    North America is the leading market share taker in the Alzheimer’s disease market.
    •    Aricept sales is expected to fall after losing its patent in November 2010
    •    Ebixa, Excelon & Namenda are on the path of becoming the next blockbuster drugs after Aricept
     
    Key Company Profiles
     
    This section provides business overview and key financial information of the companies listed below: Forest Laboratories, Eisai, H. Lundbeck A/S, Novartis, Merz GmbH & Co. KGaA, Johnson & Johnson, UCB
     
    Data Sources 
     
    Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations. 

    1. Executive Summary
     
    2. Worldwide Prevalence of Alzheimer’s Patients
    2.1 Total Number of Alzheimer’s Patients
    2.2 Total Number of Early Stage Alzheimer’s Patients
    2.3 Total Number of Late Stage Alzheimer’s Patients
     
    3. Regional Estimates for Alzheimer’s Patients
    3.1 Africa
    3.1.1 Total Number of Alzheimer’s Patients
    3.1.2 Total Number of Early Stage Alzheimer’s Patients
    3.1.3 Total Number of Late Stage Alzheimer’s Patients
    3.2 Asia
    3.2.1 Total Number of Alzheimer’s Patients
    3.2.2 Total Number of Early Stage Alzheimer’s Patients
    3.2.3 Total Number of Late Stage Alzheimer’s Patients
    3.3 Europe
    3.3.1 Total Number of Alzheimer’s Patients
    3.3.2 Total Number of Early Stage Alzheimer’s Patients
    3.3.3 Total Number Of Late Stage Alzheimer’s Patients
    3.4 Latin America & Caribbean
    3.4.1 Total Number of Alzheimer’s Patients
    3.4.2 Total Number of Early Stage Alzheimer’s Patients
    3.4.3 Total Number of Late Stage Alzheimer’s Patients
    3.5 North America
    3.5.1 Total Number of Alzheimer’s Patients
    3.5.2 Total Number of Early Stage Alzheimer’s Patients
    3.5.3 Total Number of Late Stage Alzheimer’s Patients
    3.6 Oceania
    3.6.1 Total Number of Alzheimer’s Patients
    3.6.2 Total Number of Early Stage Alzheimer’s Patients
    3.6.3 Total Number of Late Stage Alzheimer’s Patients
     
    4. Worldwide Alzheimer’s Disease Market
    4.1 North America Alzheimer’s Disease Market
    4.2 Europe Alzheimer’s Disease Market
    4.3 Rest of the World Alzheimer’s Disease Market
     
    5. Worldwide – Alzheimer’s Drug Market Share 2008 – 2009
     
    6. Worldwide – Top 10 Alzheimer’s Drug Brands Market Performance
    6.1 Exelon (Rivastigmine) – Past, Present & Future Forecast
    6.2 Aricept (Donepezil) – Past & Present Market
    6.3 Razadyne (Galantamine) (Past & Present Market) 
    6.4 Memantine (Namenda, Ebixa, Axura) 
    6.4.1 Namenda (Memantine) – Past, Present & Future Forecast
    6.4.2 Ebixa (Memantine) – Past, Present & Future Forecast
    6.4.3 Axura (Memantine) – Past, Present & Future Forecast
    6.5 Nootropil (Piracetam) – Past, Present & Future Market
    6.6 Prometax (Rivastigmine) – Past, Present & Future Forecast
    6.7 Memac (Donepezil) 
    6.8 Eranz (Donepezil) 
    6.9 Future Blockbuster Alzheimer’s Drug
     
    7. Alzheimer’s Disease Deals, 2005 – 2009
     
    8. Key Drivers of Growth in Global Alzheimer’s Disease Drug Market
    8.1 Aging Population
    8.2 Unmet Medical Needs
    8.3 Future Drugs for Disease Modification in Alzheimer’s Disease
     
    9. Key Challenges in the Global Alzheimer’s Disease Drug Market
    9.1 Lack of Validated Targets & Lack of Animal Models
    9.2 Barriers in the Design and Implementation of Clinical Trials
    9.3 Barriers in Academia & Regulatory Issues
     
    10. Key Players in the Alzheimer’s Drug Market
    10.1 Forest Laboratorie
    10.2 Eisai
    10.3 H. Lundbeck A/S
    10.4 Novartis
    10.5 Merz GmbH & Co. KGaA
    10.6 Johnson & Johnson
    10.7 UCB

    List of Figures:
     
    Figure 2 1: Worldwide – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
    Figure 2 2: Worldwide – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 – 2010
    Figure 2 3: Worldwide – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 1: Africa – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 2: Africa – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 3: Africa – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 4: Asia – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 5: Asia – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 6: Europe – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 7: Europe – Number of Patients with Early Stage Alzheimer ’s Disease (Million), 2006 – 2010
    Figure 3 8: Europe – Number of Patients with Late Stage Alzheimer ’s Disease (Million), 2006 – 2010
    Figure 3 9: Latin America & Caribbean – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 10: Latin America & Caribbean – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 11: Latin America & Caribbean – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 12: North America – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 13: North America – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 14: North America – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 15: Oceania – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 16: Oceania – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 – 2010
    Figure 3 17: Oceania – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
    Figure 4 1: Worldwide – Alzheimer’s Disease Market (Billion US$), 2006 – 2010
    Figure 4 2: Worldwide – Future Forecast for Alzheimer’s Disease Market (Billion US$), 2011 – 2015
    Figure 4 3: North America – Alzheimer’s Disease Market (Billion US$), 2006 – 2010
    Figure 4 4: North America – Future Forecast for Alzheimer’s Disease Market (Billion US$), 2011 – 2015
    Figure 4 5: Europe – Alzheimer’s Disease Market (Billion US$), 2006 – 2010
    Figure 4 6: Europe – Future Forecast for Alzheimer’s Disease Market (Billion US$), 2011 – 2015
    Figure 4 7: Rest of the World – Alzheimer’s Disease Market (Billion US$), 2006 – 2010
    Figure 4 8: Rest of the World – Forecast for Alzheimer’s Disease Market (Billion US$), 2011 – 2015
    Figure 5 1: Worldwide – Drug Companies Market Share in Alzheimer’s Disease Market (Percent), 2008
    Figure 5 2: Worldwide – Drug Companies Market Share in Alzheimer’s Disease Market (Percent), 2009
    Figure 6 1: Worldwide – Exelon Alzheimer’s Drug Sales (Million US$), 2005 – 2010
    Figure 6 2: Worldwide – Future Forecast for Exelon Alzheimer’s Drug Sales (Million US$), 2010 – 2014
    Figure 6 3: Worldwide – Aricept Alzheimer’s Drug Sales (Billion US$), 2005 – 2009
    Figure 6 4: Worldwide – Razadyne Alzheimer’s Drug Sales (Million US$), 2007 – 2009
    Figure 6 5: Worldwide – Namenda Alzheimer’s Drug Sales (Million US$), 2003 – 2010
    Figure 6 6: Worldwide – Future Forecast for Namenda Alzheimer’s Drug Sales (Million US$), 2011 – 2015
    Figure 6 7: Worldwide – Ebixa Alzheimer’s Drug Sales (Million US$), 2003 – 2010
    Figure 6 8: Worldwide – Future Forecast for Ebixa Alzheimer’s Drug Sales (Million US$), 2011 – 2014
    Figure 6 9: Worldwide – Axura Alzheimer’s Drug Sales (Million US$), 2003 – 2010
    Figure 6 10: Worldwide – Future Forecast for Axura Alzheimer’s Drug Sales (Million US$), 2011 – 2014
    Figure 6 11: Worldwide – Nootropil Alzheimer’s Drug Sales (Million US$), 2004 – 2010
    Figure 6 12: Worldwide – Future Forecast for Nootropil Alzheimer’s Drug Sales (Million US$), 2011 – 2014
    Figure 6 13: Worldwide – Prometax Alzheimer’s Drug Sales (Million US$), 2007 – 2010
    Figure 6 14: Worldwide – Future Forecast for Prometax Alzheimer’s Drug Sales (Million US$), 2011 – 2012
    Figure 6 15: Worldwide – Memac Alzheimer’s Drug Sales (Million US$), 2007 – 2009
    Figure 6 16: Worldwide – Eranz Alzheimer’s Drug Sales (Million US$), 2007 – 2009
    Figure 8 1: Worldwide – Population Aged 60 or Over: World and Development Regions, 1950, 1975, 2009, 2025 & 2050
    Figure 8 2: Worldwide – Old-Age Dependency Ratio: Major Areas, 2009 & 2050

     
    List of Tables:
     
    Table 2 1: Worldwide – Forecast For Number of Patients with Alzheimer’s (Million) 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 2 2: Worldwide – Stages of Alzheimer’s Disease
    Table 2 3: Worldwide – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million) 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 2 4: Worldwide – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 1: Africa – Forecast for Number of Patients with Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 2: Africa – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 3: Africa – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 4: Asia – Forecast for Number of Patients with Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 5: Asia – Number of Patients with early stage Alzheimer’s Disease (Million), 2006 – 2010
    Table 3 6: Asia – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 7: Asia – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 8: Europe – Forecast for Number of Patients with Alzheimer ’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 9: Europe – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 10: Europe – Forecast for number of patients with late stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 11: Latin America & Caribbean – Forecast for Number Of Patients with Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 12: Latin America & Caribbean – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 13: Latin America & Caribbean – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 14: North America – Forecast for Number of Patients with Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 15: North America – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 16: North America – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 – 2016, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 17: Oceania – Forecast for Number Of Patients with Alzheimer’s Disease (Million), 2011 – 2016, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 18: Oceania – Forecast for Number of Patients with Early Stage Alzheimer’s Disease            (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 3 19: Oceania – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
    Table 6 1: Worldwide – Bapineuzumab Drug Future Forecast Sales, (Billion US$), 2016
    Table 7 1: Worldwide – Alzheimer’s Disease Deals, 2005 – 2009
    Table 8 1: Worldwide – Population Aged 60 or Over, 65 or Over and 80 Or Over By Sex (Thousands): World, Major Areas and Regions, 2009
    Table 10 1: Forest Laboratories – Key Financials (Million US$), March 2008 – March 2010
    Table 10 2: Eisai – Key Financials (Million US$) March 2008 – March 2010
    Table 10 3: H. Lundbeck A/S – Key Financials (Million US$), 2007 – 2009
    Table 10 4: Novartis – Key Financials (Million US$), 2007 – 2009
    Table 10 5: Merz GmbH & Co. KGaA – Key Financials (Euro Million) 2007/08 – 2008/09
    Table 10 6: Johnson & Johnson – Key Financials (Million US$) 2007 – 2009
    Table 10 7: UCB – Key Financials (Million US$) 2007 – 2009


    Related Products